Trial Profile
Phase II study of Xyotax [paclitaxel poliglumex] in advanced hormone refractory prostate cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel poliglumex (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 24 Aug 2008 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
- 24 Aug 2008 Actual patient number (29) added as reported by ClinicalTrials.gov.
- 24 Aug 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.